CA2683117A1 - Immunogenic compositions - Google Patents

Immunogenic compositions Download PDF

Info

Publication number
CA2683117A1
CA2683117A1 CA002683117A CA2683117A CA2683117A1 CA 2683117 A1 CA2683117 A1 CA 2683117A1 CA 002683117 A CA002683117 A CA 002683117A CA 2683117 A CA2683117 A CA 2683117A CA 2683117 A1 CA2683117 A1 CA 2683117A1
Authority
CA
Canada
Prior art keywords
vector
antigen
immunogenic composition
viral vector
c4bp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002683117A
Other languages
English (en)
French (fr)
Inventor
Simon Draper
Adrian Hill
Fergal Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imaxio SA
Oxford University Innovation Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2683117A1 publication Critical patent/CA2683117A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002683117A 2007-04-10 2008-04-10 Immunogenic compositions Abandoned CA2683117A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0706912.3 2007-04-10
GBGB0706912.3A GB0706912D0 (en) 2007-04-10 2007-04-10 Novel viral vaccines
PCT/GB2008/001271 WO2008122817A2 (en) 2007-04-10 2008-04-10 Immunogenic compositions

Publications (1)

Publication Number Publication Date
CA2683117A1 true CA2683117A1 (en) 2008-10-16

Family

ID=38091118

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002683117A Abandoned CA2683117A1 (en) 2007-04-10 2008-04-10 Immunogenic compositions

Country Status (8)

Country Link
US (1) US20110064768A1 (enExample)
EP (1) EP2155242A2 (enExample)
JP (1) JP2010523138A (enExample)
CN (1) CN101959420A (enExample)
AU (1) AU2008235315A1 (enExample)
CA (1) CA2683117A1 (enExample)
GB (1) GB0706912D0 (enExample)
WO (1) WO2008122817A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719509D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Molecular adjuvant
BRPI0924581A2 (pt) * 2009-05-05 2016-07-19 Univ Minas Gerais seqüências geneticamente modificadas de antígenos de plasmodium vivax, composições vacinais contendo proteínas recombinantes e vírus recombinantes que expressam esses antígenos e método de vacinação dose-reforço contra malária
GB0918154D0 (en) 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
EP2557089A2 (en) * 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compositions and methods for immunomodulation
WO2014090905A1 (en) 2012-12-11 2014-06-19 Imaxio Modified coiled coil type proteins having improved properties
CN105744950A (zh) * 2013-11-05 2016-07-06 巴法里安诺迪克有限公司 用于使用表达肿瘤抗原的痘病毒和免疫检查点抑制剂的拮抗剂和/或激动剂治疗癌症的组合疗法
SG10201901735XA (en) * 2014-09-03 2019-03-28 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) filovirus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2678797A (en) * 1996-04-22 1997-11-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Heterologous boosting immunizations
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB9922361D0 (en) * 1999-09-21 1999-11-24 Isis Innovation Generating an immune response to an antigen
EP1450854A2 (en) * 2001-11-30 2004-09-01 Isis Innovation Limited Vaccine
JP2006503800A (ja) * 2002-03-13 2006-02-02 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖに対する強化された免疫応答を誘導する方法
CN1867588A (zh) * 2003-08-12 2006-11-22 阿维迪斯公司 包含c4bp核心蛋白质和单体抗原的产品及其用途
WO2005051414A1 (en) * 2003-11-26 2005-06-09 Avidis Sa Use of c4bp core region as a cd40 agonist
EP1795540A1 (en) * 2005-11-30 2007-06-13 Imaxio Multimeric complexes of antigens and an adjuvant

Also Published As

Publication number Publication date
US20110064768A1 (en) 2011-03-17
CN101959420A (zh) 2011-01-26
WO2008122817A3 (en) 2008-12-11
JP2010523138A (ja) 2010-07-15
EP2155242A2 (en) 2010-02-24
GB0706912D0 (en) 2007-05-16
AU2008235315A1 (en) 2008-10-16
WO2008122817A2 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
US9017696B2 (en) Adenovirus vectors
EP1573012B1 (en) Recombinant viral-based malaria vaccines
US8470560B2 (en) CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
US20110064768A1 (en) Immunogenic Compositions
Limbach et al. Viral vectors in malaria vaccine development
EP2678033A2 (en) Treatment and prevention of malaria
EP3209325A2 (en) Pfrh5 derived antigen for treatment of malaria
US20100278870A1 (en) Adenoviral vector-based malaria vaccines
Bruder et al. Molecular vaccines for malaria
ES2377964T3 (es) Vacunas contra la malaria basadas en virus recombinante
Xu et al. vaccine targeting plasmodium blood-stage antigens elicits immune response and protects against malaria with protein
US9254316B2 (en) Adenoviral vector-based malaria vaccines
EP4265271A2 (en) Vaccine immunogens
Nussenzweig et al. Plasmodium yoelii
WO2014188212A2 (en) Treatment and prevention of malaria
OA20441A (en) Vaccine immunogens.
US20150050317A1 (en) Means for Eliciting an Immune Response and a Method Therefor
Biswas Prime boost vaccination with viral vectors targeting apical membrane antigen1
CN102575256A (zh) 编码间日疟原虫抗原的经遗传修饰的序列

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130320

FZDE Discontinued

Effective date: 20151120